I agree with you. It is sad that this is the best that they could do. With as many hurdles the company has overcome, you would have thought that management would have been more aggressive at securing a better financing deal. I have been long for years, and have more shares than I should from an investment standpoint, but I truly believe that the future of this technology is huge. I am surprised that big pharma has not yet bought this company, because the cost of research and development, and the manufacture of API in the biotech world is astronomical. This technology is "cheap" compared to traditional methods even with outsourcing. I too am holding out, and will add more as opportunity arises.
Market Data 
Markets 
AI
